表紙
市場調査レポート

注入型ドラッグデリバリーの世界市場予測 2020年:無針注射器・オートインジェクター・ペン型注射器・ウェアラブルインジェクター

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home Care Setting) - Global Forecast to 2020

発行 MarketsandMarkets 商品コード 338418
出版日 ページ情報 英文 242 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
注入型ドラッグデリバリーの世界市場予測 2020年:無針注射器・オートインジェクター・ペン型注射器・ウェアラブルインジェクター Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home Care Setting) - Global Forecast to 2020
出版日: 2015年08月24日 ページ情報: 英文 242 Pages
概要

世界の注入型ドラッグデリバリー市場は2015年の3億2,610万米ドルから2020年までに5億4,780万米ドルに達すると予測され、2015年から2020年にかけては12.0%のCAGRで成長すると見込まれています。治療用途の疾患別では、がんセグメントが予測期間中において最も高いCAGRで推移すると予測されています。

当レポートでは、世界の注入型ドラッグデリバリー市場について分析し、市場の基本的構造や最新動向、主な市場促進・阻害要因、市場規模の動向見通し、種類・治療用途・利用パターン・投与形態・エンドユーザー・地域別の詳細動向、市場競争の状態、今後の技術開発・市場発展の方向性、主要企業のプロファイルなどを調査・考察しております。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 注入型ドラッグデリバリー市場:製剤別
  • 注入型ドラッグデリバリー市場:利用パターン別
  • 注入型ドラッグデリバリー市場:投与形態別
  • 注入型ドラッグデリバリー市場:治療用途別
  • 注入型ドラッグデリバリー市場の地域別スナップショット

第5章 市場概要

  • イントロダクション
  • 市場区分
    • 種類別
    • 治療用途別
    • 利用パターン別
    • 投与形態別
    • エンドユーザー別
    • 地域別
  • 市場ダイナミクス
  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第6章 産業動向

  • イントロダクション
  • デバイス
    • 従来型注入デバイス
      • マテリアル別
      • 製品別
      • ユーザビリティ別
    • 自己注射デバイス
      • 無針注射器
      • オートインジェクター
      • ペン型注射器
      • ウェアラブルインジェクター
      • その他のデバイス
  • 製剤
    • 従来型ドラッグデリバリー
      • ソリューション
      • 再構成/凍結乾燥製剤
      • 懸濁液 (サスペンション)
      • 乳濁液 (エマルション)
    • 新しいドラッグデリバリー製剤
      • コロイド分散
      • 微小粒子
    • 長時間作用型 (持続型) 注入製剤

第7章 モジュール型UPS市場分析:ソリューション別

  • イントロダクション
  • 自己免疫疾患
    • リウマチ性関節炎
    • 多発性硬化症
    • クローン病
    • 乾癬
    • その他の自己免疫疾患
  • ホルモン障害
    • 糖尿病
    • 貧血
    • リプロダクティブヘルス疾患
    • 骨粗しょう症
    • 成長ホルモン欠損症 (GHD)
  • 希少疾患
  • がん
  • その他
    • 疼痛管理
    • アレルギー治療
    • 美容治療
    • C型肝炎
    • 血友病

第8章 注入型ドラッグデリバリー市場:利用パターン別

  • イントロダクション
  • 治療
  • 予防接種
  • その他の利用パターン (輸血・血液製剤、避妊薬)

第9章 注入型ドラッグデリバリー市場:投与形態別

  • イントロダクション
  • 皮膚
  • 循環/筋骨格
  • 臓器
  • 中枢神経系

第10章 注入型ドラッグデリバリー市場:エンドユーザー別

  • イントロダクション
  • 病院・診療所
  • 在宅医療現場
  • 研究ラボ
  • 医薬品・バイオテクノロジー企業
  • その他のエンドユーザー

第11章 注入型ドラッグデリバリー市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他 (ROW)

第12章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合状況・動向

第13章 企業プロファイル

  • イントロダクション
  • BAXTER INTERNATIONAL, INC.
  • BECTON, DICKINSON AND COMPANY
  • GERRESHEIMER AG
  • PFIZER, INC.
  • SCHOTT AG
  • ALKERMES PLC
  • ELI LILLY AND COMPANY
  • SANDOZ
  • テルモ
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

第14章 付録

図表リスト

目次
Product Code: MD 3680

The injectable drug delivery market is expected to reach $547.8 billion by 2020 from $326.1 billion in 2015, growing at a CAGR of 12.0% from 2015 to 2020. The market is categorized on the basis of type, therapeutic application, usage pattern, mode of administration, end user, and region. The therapeutic application market is further segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. The oncology segment is expected to witness the highest CAGR in the forecast period.

Factors such as rising incidences of chronic diseases, growth of the biologics market, demand of self-injection devices, and technological advancements, are driving the growth of the injectable drug delivery market. In addition, emphasis on innovation of formulations and improving the delivery of pharmaceuticals is also contributing to the growth of the market. For instance, in November 2012, COMPACT (Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets), a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced the launch of a €30 million ($38.5 million) project, which focuses on improving the delivery of biopharmaceuticals. The consortium would address the major bottlenecks in the development of novel innovative medicines based on biological macromolecules, such as proteins/peptides and oligonucleotides. Such investments are fueling the growth of the market.

Asia is expected to be the fastest-growing country in the injectable drug delivery market. High growth in this market can be attributed to the increased demand for injectable insulin and self-injection devices, particularly pen injectors which are used in the treatment of diabetes.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the injectable drug delivery market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms to garner a greater market share. Firms purchasing the report can use one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the injectable drug delivery market. The report analyzes this market by type, therapeutic application, usage pattern, mode of administration, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the injectable drug delivery market
  • Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the injectable drug delivery market
  • Market Development: Comprehensive information about lucrative markets. The report analyzes the market for various injectable drug delivery across countries
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the injectable drug delivery market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. KEY DATA FROM SECONDARY SOURCES
  • 2.4. KEY DATA FROM PRIMARY SOURCES
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION
  • 4.2. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
  • 4.3. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
  • 4.4. INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE INJECTABLE DRUG DELIVERY MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY TYPE
    • 5.2.2. BY THERAPEUTIC APPLICATION
    • 5.2.3. BY USAGE PATTERN
    • 5.2.4. BY MODE OF ADMINISTRATION
    • 5.2.5. BY END USER
    • 5.2.6. BY REGION
  • 5.3. MARKET DYNAMICS
  • 5.4. DRIVERS
    • 5.4.1. RISING PREVALENCE OF CHRONIC DISEASES
    • 5.4.2. INCREASE IN DEMAND FOR SELF-INJECTION DEVICES
    • 5.4.3. GROWTH OF THE BIOLOGICS MARKET
    • 5.4.4. TECHNOLOGICAL ADVANCEMENTS
  • 5.5. RESTRAINTS
    • 5.5.1. NEEDLESTICK INJURIES AND INFECTIONS
  • 5.6. OPPORTUNITIES
    • 5.6.1. INCREASE IN DEMAND FOR BIOSIMILARS AND GENERIC INJECTABLES
      • 5.6.1.1. Biosimilars
      • 5.6.1.2. Generic injectables
    • 5.6.2. CONTRACEPTIVE INJECTABLES
  • 5.7. CHALLENGES
    • 5.7.1. PRODUCT RECALLS
    • 5.7.2. REGULATORY HURDLES
    • 5.7.3. STABILITY OF PRODUCTS
    • 5.7.4. STERILITY OF INJECTIONS
    • 5.7.5. PREFERENCE FOR OTHER MODES OF DRUG DELIVERY

6. INJECTABLE DRUG DELIVERY MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. DEVICES
    • 6.2.1. CONVENTIONAL INJECTION DEVICES
      • 6.2.1.1. By Material
        • 6.2.1.1.1. Glass
        • 6.2.1.1.2. Plastic
      • 6.2.1.2. By Product
        • 6.2.1.2.1. Fillable syringes
        • 6.2.1.2.2. Prefilled syringes
      • 6.2.1.3. By Usability
        • 6.2.1.3.1. Reusable syringes
        • 6.2.1.3.2. Disposable syringes
    • 6.2.2. SELF-INJECTION DEVICES
      • 6.2.2.1. Needle-free injectors
        • 6.2.2.1.1. By product
        • 6.2.2.1.1.1. Fillable needle-free injectors
        • 6.2.2.1.1.2. Prefilled needle-free injectors
        • 6.2.2.1.2. By technology
        • 6.2.2.1.2.1. Jet-based needle-free injectors
        • 6.2.2.1.2.2. Spring-based Needle-free injectors
        • 6.2.2.1.2.3. Laser-powered needle-free injectors
        • 6.2.2.1.2.4. Vibration-based needle-free injectors
        • 6.2.2.1.3. By usability
        • 6.2.2.1.3.1. Reusable needle-free injectors
        • 6.2.2.1.3.2. Disposable needle-free injectors
      • 6.2.2.2. Autoinjectors
        • 6.2.2.2.1. By product
        • 6.2.2.2.1.1. Fillable Autoinjectors
        • 6.2.2.2.1.2. Prefilled Autoinjectors
        • 6.2.2.2.2. By technology
        • 6.2.2.2.2.1. Automated Autoinjectors
        • 6.2.2.2.2.2. Manual Autoinjectors
        • 6.2.2.2.3. By design
        • 6.2.2.2.3.1. Standardized Autoinjectors
        • 6.2.2.2.3.2. Customized Autoinjectors
        • 6.2.2.2.4. By usability
        • 6.2.2.2.4.1. Reusable Autoinjectors
        • 6.2.2.2.4.2. Disposable Autoinjectors
      • 6.2.2.3. Pen injectors
        • 6.2.2.3.1. By product
        • 6.2.2.3.1.1. Single-chambered Pen Injectors
        • 6.2.2.3.1.2. Dual-chambered Pen Injectors
        • 6.2.2.3.2. By design
        • 6.2.2.3.2.1. Standard Pen Injectors
        • 6.2.2.3.2.2. Customized Pen Injectors
        • 6.2.2.3.3. By usability
        • 6.2.2.3.3.1. Reusable Pen Injectors
        • 6.2.2.3.3.2. Disposable Pen Injectors
      • 6.2.2.4. Wearable injectors
      • 6.2.2.5. Other Devices
  • 6.3. FORMULATIONS
    • 6.3.1. CONVENTIONAL DRUG DELIVERY
      • 6.3.1.1. SOLUTIONS
      • 6.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
      • 6.3.1.3. SUSPENSIONS
      • 6.3.1.4. EMULSIONS
    • 6.3.2. NOVEL DRUG DELIVERY FORMULATIONS
      • 6.3.2.1. COLLOIDAL DISPERSIONS
        • 6.3.2.1.1. LIPOSOMES
        • 6.3.2.1.2. NIOSOMES
        • 6.3.2.1.3. POLYMERIC/MIXED MICELLES
        • 6.3.2.1.4. NANOPARTICLES
        • 6.3.2.1.4.1. NANOSUSPENSIONS
        • 6.3.2.1.4.2. NANOEMULSIONS/MICROEMULSIONS
        • 6.3.2.1.4.3. SOLID-LIPID NANOPARTICLES
      • 6.3.2.2. MICROPARTICLES
        • 6.3.2.2.1. MICROSPHERES
        • 6.3.2.2.2. MICROCAPSULES
    • 6.3.3. LONG-ACTING INJECTION FORMULATIONS

7. INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. AUTOIMMUNE DISEASES
    • 7.2.1. RHEUMATOID ARTHRITIS
    • 7.2.2. MULTIPLE SCLEROSIS
    • 7.2.3. CROHN'S DISEASE
    • 7.2.4. PSORIASIS
    • 7.2.5. OTHER AUTOIMMUNE DISEASES
  • 7.3. HORMONAL DISORDERS
    • 7.3.1. DIABETES
    • 7.3.2. ANEMIA
    • 7.3.3. REPRODUCTIVE HEALTH DISEASE
    • 7.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
    • 7.3.5. OSTEOPOROSIS
    • 7.3.6. GROWTH HORMONE DEFICIENCY (GHD)
  • 7.4. ORPHAN DISEASES
  • 7.5. ONCOLOGY
  • 7.6. OTHERS
    • 7.6.1. PAIN MANAGEMENT
    • 7.6.2. ALLERGY TREATMENT
    • 7.6.3. AESTHETIC TREATMENTS
    • 7.6.4. HEPATITIS C
    • 7.6.5. HEMOPHILIA

8. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

  • 8.1. INTRODUCTION
  • 8.2. CURATIVE CARE
  • 8.3. IMMUNIZATION
  • 8.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION AND BLOOD PRODUCTS, AND CONTRACEPTIVES)

9. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

  • 9.1. INTRODUCTION
  • 9.2. SKIN
  • 9.3. CIRCULATORY/MUSCULOSKELETAL
  • 9.4. ORGANS
  • 9.5. CENTRAL NERVOUS SYSTEM

10. INJECTABLE DRUG DELIVERY MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. HOSPITALS AND CLINICS
  • 10.3. HOME CARE SETTINGS
  • 10.4. RESEARCH LABORATORIES
  • 10.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 10.6. OTHER END USERS

11. INJECTABLE DRUG DELIVERY MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
    • 11.2.2. CANADA
  • 11.3. EUROPE
    • 11.3.1. GERMANY
    • 11.3.2. FRANCE
    • 11.3.3. U.K.
    • 11.3.4. ITALY
    • 11.3.5. SPAIN
    • 11.3.6. REST OF EUROPE (ROE)
  • 11.4. ASIA
  • 11.5. REST OF THE WORLD (ROW)

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SITUATIONS & TRENDS
    • 12.3.1. NEW PRODUCT LAUNCHES
    • 12.3.2. EXPANSIONS AND INVESTMENTS
    • 12.3.3. ACQUISITIONS
    • 12.3.4. COLLABORATIONS

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. INTRODUCTION
  • 13.2. BAXTER INTERNATIONAL, INC.
  • 13.3. BECTON, DICKINSON AND COMPANY
  • 13.4. GERRESHEIMER AG
  • 13.5. PFIZER, INC.
  • 13.6. SCHOTT AG
  • 13.7. ALKERMES PLC
  • 13.8. ELI LILLY AND COMPANY
  • 13.9. SANDOZ
  • 13.10. TERUMO CORPORATION
  • 13.11. TEVA PHARMACEUTICAL INDUSTRIES LTD.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. OTHER RECENT DEVELOPMENTS
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RT: REAL-TIME MARKET INTELLIGENCE
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS (2013-2015)
  • TABLE 2: RISING PREVALENCE OF CHRONIC DISEASES ACROSS THE GLOBE IS A MAJOR FACTOR DRIVING MARKET GROWTH
  • TABLE 3: NEEDLESTICK INJURIES AND INFECTIONS ARE MAJOR FACTORS LIMITING THE GROWTH OF THE MARKET
  • TABLE 4: INCREASE IN DEMAND FOR BIOSIMILARS OFFERS AN ARRAY OF OPPORTUNITIES FOR THE MARKET
  • TABLE 5: EXAMPLES OF PRODUCT RECALLS (2010-2015)
  • TABLE 6: PRODUCT RECALLS ARE A SIGNIFICANT CHALLENGE FOR MARKET GROWTH
  • TABLE 7: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 8: INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 9: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 10: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 11: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 12: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY MATERIAL, 2013-2020 (USD MILLION)
  • TABLE 13: CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 14: CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 15: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 16: CONVENTIONAL FILLABLE INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 17: CONVENTIONAL PREFILLED INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 18: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY USABILITY, 2013-2020 (USD MILLION)
  • TABLE 19: CONVENTIONAL REUSABLE INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 20: CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 21: SELF-INJECTION DEVICES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 22: SELF-INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 23: NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 24: NEEDLE-FREE INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 25: FILLABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 26: PREFILLED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 27: NEEDLE-FREE INJECTORS MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 28: JET-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 29: SPRING-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 30: LASER-POWERED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 31: VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 32: NEEDLE-FREE INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (USD MILLION)
  • TABLE 33: REUSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 34: DISPOSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 35: AUTOINJECTOR DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 36: AUTOINJECTOR DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 37: FILLABLE AUTOINJECTOR DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 38: PREFILLED AUTOINJECTOR DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 39: AUTOINJECTOR DEVICES MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 40: AUTOMATED AUTOINJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 41: MANUAL AUTOINJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 42: AUTOINJECTORS MARKET SIZE, BY DESIGN, 2013-2020 (USD MILLION)
  • TABLE 43: STANDARDIZED AUTOINJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 44: CUSTOMIZED AUTOINJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 45: AUTOINJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (USD MILLION)
  • TABLE 46: REUSABLE AUTOINJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 47: DISPOSABLE AUTOINJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 48: PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 49: PEN INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 50: SINGLE-CHAMBERED PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 51: DUAL-CHAMBERED PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 52: PEN INJECTORS MARKET SIZE, BY DESIGN, 2013-2020 (USD MILLION)
  • TABLE 53: STANDARD PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 54: CUSTOMIZED PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 55: PEN INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (USD MILLION)
  • TABLE 56: REUSABLE PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 57: DISPOSABLE PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 58: WEARABLE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 59: OTHER DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 60: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 61: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 62: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 63: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 64: SOLUTIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 65: RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 66: SUSPENSIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 67: EMULSIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 68: NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 69: NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 70: COLLOIDAL DISPERSION MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 71: COLLOIDAL DISPERSION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 72: LIPOSOMES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 73: NIOSOMES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 74: POLYMERIC/MIXED MICELLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 75: NANOPARTICLES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 76: NANOPARTICLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 77: NANOSUSPENSIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 78: NANOEMULSIONS/MICROEMULSIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 79: SOLID-LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 80: MICROPARTICLES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 81: MICROPARTICLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 82: MICROSPHERES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 83: MICROCAPSULES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 84: LONG-ACTING INJECTION FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 85: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 86: INJECTABLE DRUG DELIVERY MARKET SIZE FOR AUTOIMMUNE DISEASES, BY INDICATION, 2013-2020 (USD MILLION)
  • TABLE 87: INJECTABLE DRUG DELIVERY MARKET SIZE FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 88: INJECTABLE DRUG DELIVERY MARKET SIZE FOR RHEUMATOID ARTHRITIS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 89: INJECTABLE DRUG DELIVERY MARKET SIZE FOR MULTIPLE SCLEROSIS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 90: INJECTABLE DRUG DELIVERY MARKET SIZE FOR CROHN'S DISEASE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 91: INJECTABLE DRUG DELIVERY MARKET SIZE FOR PSORIASIS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 92: INJECTABLE DRUG DELIVERY MARKET SIZE FOR OTHER AUTOIMMUNE DISEASES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 93: INJECTABLE DRUG DELIVERY MARKET SIZE FOR HORMONAL DISORDERS, BY INDICATION, 2013-2020 (USD MILLION)
  • TABLE 94: INJECTABLE DRUG DELIVERY MARKET SIZE FOR HORMONAL DISORDERS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 95: INJECTABLE DRUG DELIVERY MARKET SIZE FOR DIABETES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 96: INJECTABLE DRUG DELIVERY MARKET SIZE FOR ANEMIA, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 97: INJECTABLE DRUG DELIVERY MARKET SIZE FOR REPRODUCTIVE HEALTH DISEASE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 98: INJECTABLE DRUG DELIVERY MARKET SIZE FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 99: INJECTABLE DRUG DELIVERY MARKET SIZE FOR OSTEOPOROSIS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 100: INJECTABLE DRUG DELIVERY MARKET SIZE FOR GROWTH HORMONE DEFICIENCY (GHD), BY REGION, 2013-2020 (USD MILLION)
  • TABLE 101: INJECTABLE DRUG DELIVERY MARKET SIZE FOR ORPHAN DISEASES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 102: INJECTABLE DRUG DELIVERY MARKET SIZE FOR ONCOLOGY, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 103: INJECTABLE DRUG DELIVERY MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY INDICATION, 2013-2020 (USD MILLION)
  • TABLE 104: INJECTABLE DRUG DELIVERY MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 105: INJECTABLE DRUG DELIVERY MARKET SIZE FOR PAIN MANAGEMENT, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 106: INJECTABLE DRUG DELIVERY MARKET SIZE FOR ALLERGY TREATMENT, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 107: INJECTABLE DRUG DELIVERY MARKET SIZE FOR AESTHETIC TREATMENTS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 108: INJECTABLE DRUG DELIVERY MARKET SIZE FOR HEPATITIS C, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 109: INJECTABLE DRUG DELIVERY MARKET SIZE FOR HEMOPHILIA, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 110: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 111: CURATIVE CARE MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 112: IMMUNIZATION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 113: OTHER USAGE PATTERNS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 114: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 115: SKIN ADMINISTRATION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 116: CIRCULATORY/MUSCULOSKELETAL ADMINISTRATION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 117: ORGAN ADMINISTRATION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 118: CENTRAL NERVOUS SYSTEM ADMINISTRATION MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 119: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 120: INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 121: HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 122: HOME CARE SETTINGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 123: RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 124: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 125: OTHER END USERS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 126: INJECTABLE DRUG DELIVERY MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 127: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 128: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 129: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 130: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 131: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 132: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 133: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 134: NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 135: U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 136: U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 137: U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 138: U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 139: U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 140: U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 141: U.S.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 142: CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 143: CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 144: CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 145: CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 146: CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 147: CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 148: CANADA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 149: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 150: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 151: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 152: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 153: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 154: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 155: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 156: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 157: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 158: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 159: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 160: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 161: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 162: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 163: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 164: FRANCE :INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 165: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 166: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 167: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 168: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 169: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 170: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 171: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 172: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 173: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 174: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 175: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 176: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 177: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 178: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 179: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 180: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 181: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 182: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 183: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 184: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 185: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 186: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 187: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE , BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 188: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 189: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 190: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 191: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 192: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 193: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 194: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 195: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 196: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 197: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 198: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 199: ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 200: ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 201: ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 202: ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 203: ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 204: ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 205: ASIA: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 206: ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 207: ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 208: ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 (USD MILLION)
  • TABLE 209: ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 210: ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 (USD MILLION)
  • TABLE 211: ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 (USD MILLION)
  • TABLE 212: ROW: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 213: NEW PRODUCT LAUNCHES, 2014-2015
  • TABLE 214: MAJOR APPROVALS, 2014-2015
  • TABLE 215: EXPANSIONS AND INVESTMENTS, 2013-2015
  • TABLE 216: ACQUISITIONS, 2014-2015
  • TABLE 217: COLLABORATIONS, 2014-2015

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2015 VS. 2020
  • FIGURE 7: INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2015 VS. 2020
  • FIGURE 8: HOSPITALS AND CLINICS TO FORM THE LARGEST END-USER SEGMENT
  • FIGURE 9: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2015 VS. 2020
  • FIGURE 10: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020
  • FIGURE 11: THE CURATIVE CARE SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 12: SKIN SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015
  • FIGURE 13: HORMONAL DISORDERS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015
  • FIGURE 14: ASIA TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 15: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY TYPE
  • FIGURE 16: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY THERAPEUTIC APPLICATION
  • FIGURE 17: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY USAGE PATTERN
  • FIGURE 18: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY MODE OF ADMINISTRATION
  • FIGURE 19: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY END USER
  • FIGURE 20: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY REGION
  • FIGURE 21: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTABLE DRUG DELIVERY MARKET
  • FIGURE 22: INJECTABLE DRUG DELIVERY THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2013-2020 (USD MILLION)
  • FIGURE 23: THERAPEUTIC APPLICATIONS: ONCOLOGY TO SHOW HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 24: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN: CURATIVE CARE SEGMENT TO HOLD LARGEST SHARE
  • FIGURE 25: INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION: SKIN SEGMENT TO SHOW HIGHEST GROWTH
  • FIGURE 26: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY END USER
  • FIGURE 27: INJECTABLE DRUG DELIVERY MARKET, BY END USER: HOSPITALS AND CLINICS TO HOLD LARGEST MARKET SHARE IN 2015
  • FIGURE 28: NORTH AMERICA TO HOLD THE LARGEST SHARE OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET (2015)
  • FIGURE 29: EUROPEAN INJECTABLE DRUG DELIVERY MARKET SNAPSHOT (2015)
  • FIGURE 30: ROE: SELF-INJECTION DEVICES MARKET SNAPSHOT
  • FIGURE 31: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET (2015)
  • FIGURE 32: RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE INJECTABLE DRUG DELIVERY MARKET IN THE ROW (2015)
  • FIGURE 33: NEW PRODUCT LAUNCHES, KEY GROWTH STRATEGY BETWEEN 2012 & 2015
  • FIGURE 34: GLOBAL INJECTABLE DRUG DELIVERY MARKET SHARE, BY KEY PLAYER (2014)
  • FIGURE 35: MARKET EVOLUTION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS & EXPANSIONS ARE FUELING MARKET GROWTH
  • FIGURE 36: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY ADOPTED BY LEADING PLAYERS, 2014
  • FIGURE 37: PRODUCT BENCHMARKING FOR TOP 5 PLAYERS
  • FIGURE 38: BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • FIGURE 39: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 40: GERRESHEIMER AG: COMPANY SNAPSHOT
  • FIGURE 41: PFIZER, INC.: COMPANY SNAPSHOT
  • FIGURE 42: SCHOTT AG: COMPANY SNAPSHOT
  • FIGURE 43: ALKERMES PLC: COMPANY SNAPSHOT
  • FIGURE 44: ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 45: SANDOZ: COMPANY SNAPSHOT
  • FIGURE 46: TERUMO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 47: TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
Back to Top